Edwards CM, Stanley SA, Davis R,  et al. Exendin-4 reduces fasting and  postprandial glucose and decreases  energy intake in healthy volunteers.  AmJ Physiol Endocrinol Metal;. 2001;  281:E155-E161.  Szayna M, Doyle ME, BetkeyJA, et  al. Exendin-4 decelerates food in-  take, weight gain, and fat deposi-  tion in Zucker rats. Endocrinology.  2000;141:1936-1941. 29.  30. Drucker DJ. Enhancing incretin ac-  tion for the treatment of type 2 dia-  betes. Diabetes Care. 2003;26:2929-  2940.  Lewington S, Clarke R, Qizilbash N,  et al, for the Prospective Studies  Collaboration. Age-specific rele-  vance of usual blood pressure to  vascular mortality: A meta-analysis  of individual data for one million  adults in 61 prospective studies [pub-  lished correction appears in Lancet.  2003;361:1060]. Lancet. 2002;360:  1903-1913.  Address correspondence to: Robert G. Brodows, MD, Eli Lilly and  Company, Lilly Corporate Center, Drop Code 6015, Indianapolis, IN  46285. E-marl: rgbrodows@lilly.com